{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003920","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.203319+00:00","generated_at":"2026-06-07T02:09:54.691896+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios outlines 2024 milestones; positive Phase 3 mitapivat data in thalassemia; multiple potential approvals by 2026","bullets":["Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia met primary endpoint (data Jan 3, 2024).","NDA for mitapivat in thalassemia planned by end of 2024; potential FDA approval in 2025.","Four additional Phase 3 readouts expected by end of 2025: ENERGIZE-T, ACTIVATE kids-T, RISE UP, ACTIVATE kids.","Potential FDA approvals: thalassemia 2025, sickle cell disease 2026, pediatric PK deficiency 2026.","Cash position expected to support operations and pipeline expansion at least into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003920","json":"https://secwatch.observer/filing/0001193125-24-003920.json","markdown":"https://secwatch.observer/filing/0001193125-24-003920.md","text":"https://secwatch.observer/filing/0001193125-24-003920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312524003920/0001193125-24-003920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312524003920/d275955d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:09:54.691896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}